Christopher Yea is CHIEF DEVELOPMENT OFFICER of KalVista Pharmaceuticals, Inc.. Currently has a direct ownership of 72,895 shares of KALV, which is worth approximately $868,908. The most recent transaction as insider was on Feb 20, 2024, when has been sold 12,053 shares (Common Stock) at a price of $14.11 per share, resulting in proceeds of $170,067. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 72.9K
14.19% 3M change
95.38% 12M change
Total Value Held $868,908

Christopher Yea Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 20 2024
SELL
Open market or private sale
$170,067 $14.11 p/Share
12,053 Reduced 14.19%
72,895 Common Stock
Feb 17 2024
BUY
Exercise of conversion of derivative security
-
18,788 Added 18.11%
84,948 Common Stock
Feb 14 2024
SELL
Open market or private sale
$598,688 $15.01 p/Share
39,886 Reduced 37.61%
66,160 Common Stock
Feb 11 2024
BUY
Grant, award, or other acquisition
-
60,000 Added 36.13%
106,046 Common Stock
Nov 20 2023
SELL
Open market or private sale
$58,539 $8.23 p/Share
7,113 Reduced 13.38%
46,046 Common Stock
Nov 17 2023
BUY
Exercise of conversion of derivative security
-
11,497 Added 17.78%
53,159 Common Stock
Aug 18 2023
SELL
Open market or private sale
$76,633 $10.73 p/Share
7,142 Reduced 14.63%
41,662 Common Stock
Aug 17 2023
BUY
Exercise of conversion of derivative security
-
11,494 Added 19.06%
48,804 Common Stock
May 18 2023
SELL
Open market or private sale
$26,404 $10.14 p/Share
2,604 Reduced 6.52%
37,310 Common Stock
May 17 2023
BUY
Exercise of conversion of derivative security
-
4,205 Added 9.53%
39,914 Common Stock
Feb 17 2023
SELL
Open market or private sale
$20,888 $7.66 p/Share
2,727 Reduced 7.09%
35,709 Common Stock
Feb 17 2023
BUY
Exercise of conversion of derivative security
-
4,204 Added 9.86%
38,436 Common Stock
Nov 18 2022
SELL
Open market or private sale
$6,196 $5.44 p/Share
1,139 Reduced 3.22%
34,232 Common Stock
Nov 17 2022
BUY
Exercise of conversion of derivative security
-
1,774 Added 4.78%
35,371 Common Stock
Aug 17 2022
SELL
Open market or private sale
$17,129 $14.96 p/Share
1,145 Reduced 3.3%
33,597 Common Stock
Aug 17 2022
BUY
Exercise of conversion of derivative security
-
1,773 Added 4.86%
34,742 Common Stock
Nov 01 2021
SELL
Open market or private sale
$90,350 $18.07 p/Share
5,000 Reduced 13.17%
32,969 Common Stock
Aug 02 2021
SELL
Open market or private sale
$102,600 $20.52 p/Share
5,000 Reduced 11.64%
37,969 Common Stock
May 03 2021
SELL
Open market or private sale
$124,200 $24.84 p/Share
5,000 Reduced 10.42%
42,969 Common Stock
Feb 23 2021
SELL
Open market or private sale
$502,350 $33.49 p/Share
15,000 Reduced 23.82%
47,969 Common Stock
Oct 29 2020
SELL
Open market or private sale
$87,400 $17.48 p/Share
5,000 Reduced 7.36%
62,969 Common Stock
Oct 21 2020
SELL
Open market or private sale
$110,907 $18.35 p/Share
6,044 Reduced 8.17%
67,969 Common Stock
Oct 20 2020
SELL
Open market or private sale
$140,097 $17.64 p/Share
7,942 Reduced 9.69%
74,013 Common Stock
Oct 16 2020
SELL
Open market or private sale
$15,538 $17.0 p/Share
914 Reduced 1.1%
81,955 Common Stock
CY

Christopher Yea

CHIEF DEVELOPMENT OFFICER
Cambridge, MA

Track Institutional and Insider Activities on KALV

Follow KalVista Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KALV shares.

Notify only if

Insider Trading

Get notified when an Kal Vista Pharmaceuticals, Inc. insider buys or sells KALV shares.

Notify only if

News

Receive news related to KalVista Pharmaceuticals, Inc.

Track Activities on KALV